Status:
RECRUITING
AURORA Study-A Transformative Approach to Support PrEP Medication Persistence
Lead Sponsor:
WV Health Right, Inc.
Collaborating Sponsors:
ViiV Healthcare
Conditions:
HIV Infections
Eligibility:
All Genders
18+ years
Brief Summary
This study is designed to test the hypothesis that, compared to oral PrEP, use of CAB-LA in underserved populations in a real-world setting supported by a digital health companion program will be asso...
Detailed Description
The study will evaluate the extent to which real-world use of CAB-LA for PrEP in underserved populations impacts PrEP adherence, persistence, retention-in-care, and PROs compared with oral PrEP. Addit...
Eligibility Criteria
Inclusion
- Initiation of or current user of PrEP with CAB-LA, daily FTC/TDF, or daily FTC/TAF prescribed in accordance with the WVHR standard of care practices (based practices on CDC PrEP 2021 Clinical Practice Guidelines) by a licensed HCP
- PrEP dispensed by WVHR pharmacy
- Access to a smart phone
Exclusion
- Receiving HIV PrEP care outside of WVHR
- Positive HIV diagnosis
- Contraindication to oral or injectable PrEP therapy
- Receiving oral bridging therapy prior to injectable PrEP therapy
Key Trial Info
Start Date :
November 30 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2025
Estimated Enrollment :
105 Patients enrolled
Trial Details
Trial ID
NCT06072443
Start Date
November 30 2023
End Date
June 30 2025
Last Update
June 25 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
West Virginia Health Right
Charleston, West Virginia, United States, 25311